Celldex TherapeuticsCLDX +3.43%57 PS Ratio is 2,710.00 as of Jun. 28, 2026, which is 1589% above its 10-year median of 160.48. GuruFocus rates CLDX with a GF Score™ of 57/100 and a GF Value™ of $6.88 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 936 Biotechnology companies, Celldex Therapeutics ranks worse than 97.86% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Celldex Therapeutics's share price is $35.23.
Celldex Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.01. Hence, Celldex Therapeutics's PS Ratio for today is 2,710.00.
Warning Sign:
Celldex Therapeutics Inc stock PS Ratio (=2710) is close to 10-year high of 2710.
The historical rank and industry rank for Celldex Therapeutics's PS Ratio or its related term are showing as below:
CLDX'
s PS Ratio Range Over the Past 10 Years
Min: 2.54 Med: 160.48 Max: 2710
Current: 2710
During the past 13 years, Celldex Therapeutics's highest PS Ratio was 2710.00. The lowest was 2.54. And the median was 160.48.
CLDX's PS Ratio is ranked worse than 97.86% of 936
companies
in the Biotechnology industry
Industry Median: 9.165
vs CLDX: 2710.00
Celldex Therapeutics Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Celldex Therapeutics was -88.60% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -22.80% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -26.70% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -30.90% per year.
During the past 13 years, Celldex Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 327.30% per year. The lowest was -67.30% per year. And the median was -22.80% per year.
Back to Basics: PS Ratio
Celldex Therapeutics (NAS:CLDX) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Celldex Therapeutics PS Ratio Related Terms
Celldex Therapeutics PS Ratio Historical Data
* Premium members only.
The historical data trend for Celldex Therapeutics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Celldex Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celldex Therapeutics PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Celldex Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Celldex Therapeutics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Celldex Therapeutics's Share Price of today is $35.23. Celldex Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Celldex Therapeutics (CLDX) has a PS Ratio of 2,710.00 as of Jun. 28, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Celldex Therapeutics and its competitors. This is 1589% above median its historical median of 160.48. Over the past decade, Celldex Therapeutics' PS Ratio has ranged from 2.54 to 2,710.00. According to the industry distribution chart, Celldex Therapeutics ranks #916 out of 936 companies in the Biotechnology industry, placing it in the top 97.9%.
Is Celldex Therapeutics' PS Ratio too high?
Celldex Therapeutics' current PS Ratio of 2,710.00 is 1589% above median its 10-year median of 160.48. Over the past 10 years, this metric has ranged from a low of 2.54 to a high of 2,710.00. The Biotechnology industry median PS Ratio is 9.17. Celldex Therapeutics' value of 2,710.00 is 29469% above this industry median. Based on the distribution chart, Celldex Therapeutics ranks #916 out of 936 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Celldex Therapeutics has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Celldex Therapeutics' PS Ratio compare to IMNM and ELVN?
According to the Biotechnology industry distribution chart, Celldex Therapeutics ranks #916 out of 936 companies for PS Ratio. This places Celldex Therapeutics in the lower half of its industry. The industry median PS Ratio is 9.17. Celldex Therapeutics' value of 2,710.00 is 29469% above this benchmark. Historically, Celldex Therapeutics' own PS Ratio has ranged from 2.54 to 2,710.00 over the past decade. While the company's 10-year median is 160.48 vs. the industry median of 9.17, Celldex Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.17, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Celldex Therapeutics's current PS Ratio of 2,710.00 is 29469% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Celldex Therapeutics and its competitors. For the Biotechnology industry, the median PS Ratio is 9.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celldex Therapeutics's current PS Ratio is 2,710.00, which is 1589% above median its own 10-year median of 160.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celldex Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Celldex Therapeutics (CLDX) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.88, compared to a current price of $35.23 — trading 412.1% above its estimated fair value. The current PS Ratio is 2,710.00, which is 1589% above median its 10-year median of 160.48 and 29469% above the Biotechnology industry median of 9.17. Celldex Therapeutics' overall GF Score™ is 57/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Celldex Therapeutics (CLDX), the current PS Ratio is 2,710.00 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Celldex Therapeutics (CLDX) Overvalued in 2026?
Based on GuruFocus' analysis, Celldex Therapeutics stock appears to be overvalued.
The current stock price of $35.23 is trading 412.1% above its estimated GF Value™ of $6.88.
GuruFocus considers Celldex Therapeutics to be Significantly Overvalued.
Key valuation signals for CLDX:
PS Ratio: 2,710.00 (1589% above median its 10-year median of 160.48)
GF Value™: $6.88 vs. price of $35.23 (412.1% above fair value)
Industry Position: 29469% above the Biotechnology median (#916 of 936)
No single metric tells the full story. See the CLDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
57GF Score
Get the complete analysis for CLDX
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLDX has been successfully added to your 
